88 related articles for article (PubMed ID: 23503545)
1. Four-year follow-up study of pharmacological treatment in pathological gamblers.
Rosenberg O; Dinur LK; Dannon PN
Clin Neuropharmacol; 2013; 36(2):42-5. PubMed ID: 23503545
[TBL] [Abstract][Full Text] [Related]
2. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.
Dannon PN; Lowengrub K; Musin E; Gonopolsky Y; Kotler M
J Clin Psychopharmacol; 2007 Dec; 27(6):620-4. PubMed ID: 18004130
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled trial of topiramate for pathological gambling.
Berlin HA; Braun A; Simeon D; Koran LM; Potenza MN; McElroy SL; Fong T; Pallanti S; Hollander E
World J Biol Psychiatry; 2013 Mar; 14(2):121-8. PubMed ID: 21486110
[TBL] [Abstract][Full Text] [Related]
4. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
Black DW; Arndt S; Coryell WH; Argo T; Forbush KT; Shaw MC; Perry P; Allen J
J Clin Psychopharmacol; 2007 Apr; 27(2):143-50. PubMed ID: 17414236
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.
Dannon PN; Lowengrub K; Musin E; Gonopolski Y; Kotler M
J Clin Psychopharmacol; 2005 Dec; 25(6):593-6. PubMed ID: 16282845
[TBL] [Abstract][Full Text] [Related]
6. [Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs].
Shoenfeld N; Bodnik D; Rosenberg O; Kotler M; Dannon P
Harefuah; 2011 Dec; 150(12):888-92, 937. PubMed ID: 22352278
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study.
Lahti T; Halme JT; Pankakoski M; Sinclair D; Alho H
Psychopharmacol Bull; 2010; 43(3):35-44. PubMed ID: 21150845
[TBL] [Abstract][Full Text] [Related]
9. Comparing topiramate with naltrexone in the treatment of alcohol dependence.
Baltieri DA; Daró FR; Ribeiro PL; de Andrade AG
Addiction; 2008 Dec; 103(12):2035-44. PubMed ID: 18855810
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.
Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S
Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276
[TBL] [Abstract][Full Text] [Related]
11. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Bystritsky A; Kerwin L; Feusner JD; Vapnik T
Psychopharmacol Bull; 2008; 41(1):46-51. PubMed ID: 18362870
[TBL] [Abstract][Full Text] [Related]
12. An open-label trial of escitalopram in the treatment of pathological gambling.
Black DW; Shaw M; Forbush KT; Allen J
Clin Neuropharmacol; 2007; 30(4):206-12. PubMed ID: 17762317
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial.
Muller JE; Wentzel I; Koen L; Niehaus DJ; Seedat S; Stein DJ
Int Clin Psychopharmacol; 2008 Jan; 23(1):43-8. PubMed ID: 18090507
[TBL] [Abstract][Full Text] [Related]
14. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.
Baltieri DA; Daró FR; Ribeiro PL; Andrade AG
Drug Alcohol Depend; 2009 Nov; 105(1-2):33-41. PubMed ID: 19595518
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram versus placebo in the treatment of dysthymic disorder.
Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
[TBL] [Abstract][Full Text] [Related]
17. The role of personality in the prediction of treatment outcome in pathological gamblers: a follow-up study.
Ramos-Grille I; Gomà-i-Freixanet M; Aragay N; Valero S; Vallès V
Psychol Assess; 2013 Jun; 25(2):599-605. PubMed ID: 23544399
[TBL] [Abstract][Full Text] [Related]
18. Pathological gambling: comorbid psychiatric diagnoses in patients and their families.
Dannon PN; Lowengrub K; Aizer A; Kotler M
Isr J Psychiatry Relat Sci; 2006; 43(2):88-92. PubMed ID: 16910370
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
